Results 31 to 40 of about 4,076 (204)

The pharmacokinetics of [18F]UCB-H revisited in the healthy non-human primate brain

EJNMMI Research, 2021
Background Positron Emission Tomography (PET) imaging of the Synaptic Vesicle glycoprotein (SV) 2A is a new tool to quantify synaptic density. [18F]UCB-H was one of the first promising SV2A-ligands to be labelled and used in vivo in rodent and human ...
Sébastien Goutal, Martine Guillermier, Guillaume Becker, Mylène Gaudin, Yann Bramoullé, André Luxen, Christian Lemaire, Alain Plenevaux, Eric Salmon, Philippe Hantraye, Olivier Barret, Nadja Van Camp   +11 more
doaj   +1 more source

Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission [PDF]

, 2016
Synaptic vesicle glycoprotein 2A (SV2A) is a prototype synaptic vesicle protein regulating action potential-dependent neurotransmitters release. SV2A also serves as a specific binding site for certain antiepileptics and is implicated in the treatment of ...
Ishihara, Shizuka, Tokudome, Kentaro, Terada, Ryo, Serikawa, Tadao, Shimizu, Saki, Sasa, Masashi, Kunisawa, Naofumi, Okumura, Takahiro, Mashimo, Tomoji, Takizawa, Akiko, Ohno, Yukihiro   +10 more
core   +1 more source

SV2A - just a synaptic vesicle protein? Unravelling the interaction of SV2A and mitochondria in the pathogenesis and therapy of Morbus Alzheimer

, 2022
199 Seiten, Illustrationen ...
openaire   +3 more sources

Identification of the antiepileptic racetam binding site in the vesicle synaptic protein 2A by molecular dynamics and docking simulations

Frontiers in Cellular Neuroscience, 2015
Synaptic vesicle protein 2A (SV2A) is an integral membrane protein necessary for the proper function of the central nervous system (CNS) and is associated to the physiopathology of epilepsy.
José eCorrea-Basurto, Roberto I. eCuevas-Hernández, Bryan V. ePhillips-Farfán, Marlet eMartínez-Archundia, Antonio eRomo-Mancillas, Gema L. eRamírez-Salinas, Óscar A. ePérez-González, José eTrujillo-Ferrara, Julieta Griselda Mendoza-Torreblanca   +8 more
doaj   +1 more source

Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE)

Molecular Brain, 2022
Synaptic vesicle glycoprotein-2 (SV2) is a family of proteins consisting of SV2A, SV2B, and SV2C. This protein family has attracted attention in recent years after SV2A was shown to be an epileptic drug target and a perhaps a biomarker of synaptic ...
Burcu A. Pazarlar, Sanjay S. Aripaka, Viktor Petukhov, Lars Pinborg, Konstantin Khodosevich, Jens D. Mikkelsen   +5 more
doaj   +1 more source

Imaging the effect of ketamine on synaptic density (SV2A) in the living brain

Molecular Psychiatry, 2022
The discovery of ketamine as a rapid and robust antidepressant marks the beginning of a new era in the treatment of psychiatric disorders. Ketamine is thought to produce rapid and sustained antidepressant effects through restoration of lost synaptic connections.
Sophie E. Holmes, Sjoerd J. Finnema, Mika Naganawa, Nicole DellaGioia, Daniel Holden, Krista Fowles, Margaret Davis, Jim Ropchan, Paul Emory, Yunpeng Ye, Nabeel Nabulsi, David Matuskey, Gustavo A. Angarita, Robert H. Pietrzak, Ronald S. Duman, Gerard Sanacora, John H. Krystal, Richard E. Carson, Irina Esterlis   +18 more
openaire   +2 more sources

Image_2_Connectivity Mapping Using a Novel sv2a Loss-of-Function Zebrafish Epilepsy Model as a Powerful Strategy for Anti-epileptic Drug Discovery.pdf

, 2022
Synaptic vesicle glycoprotein 2A (SV2A) regulates action potential-dependent neurotransmitter release and is commonly known as the primary binding site of an approved anti-epileptic drug, levetiracetam.
Lise Heylen (11561266), Patrice Godard (3476651), Yifan Zhang (119570), Michèle Partoens (12620839), Aleksandra Siekierska (11561278), Rafal M. Kaminski (12620842), Peter A. M. de Witte (11561275), James D. Mills (9418733), Michel Gillard (261248)   +8 more
core   +1 more source

Improved synthesis of SV2A targeting radiotracer [11C]UCB-J [PDF]

EJNMMI Radiopharmacy and Chemistry, 2019
Abstract Introduction [11C]UCB-J is a tracer developed for PET (positron emission tomography) that has high affinity towards synaptic vesicle glycoprotein 2A (SV2A), a protein believed to participate in the regulation of neurotransmitter release in neurons and endocrine cells.
Johanna Rokka, Eva Schlein, Jonas Eriksson   +2 more
openaire   +4 more sources

Image_1_Connectivity Mapping Using a Novel sv2a Loss-of-Function Zebrafish Epilepsy Model as a Powerful Strategy for Anti-epileptic Drug Discovery.PDF

, 2022
Synaptic vesicle glycoprotein 2A (SV2A) regulates action potential-dependent neurotransmitter release and is commonly known as the primary binding site of an approved anti-epileptic drug, levetiracetam.
Lise Heylen (11561266), Patrice Godard (3476651), Yifan Zhang (119570), Michèle Partoens (12620839), Aleksandra Siekierska (11561278), Rafal M. Kaminski (12620842), Peter A. M. de Witte (11561275), James D. Mills (9418733), Michel Gillard (261248)   +8 more
core   +1 more source

Image_3_Connectivity Mapping Using a Novel sv2a Loss-of-Function Zebrafish Epilepsy Model as a Powerful Strategy for Anti-epileptic Drug Discovery.pdf

, 2022
Synaptic vesicle glycoprotein 2A (SV2A) regulates action potential-dependent neurotransmitter release and is commonly known as the primary binding site of an approved anti-epileptic drug, levetiracetam.
Lise Heylen (11561266), Patrice Godard (3476651), Yifan Zhang (119570), Michèle Partoens (12620839), Aleksandra Siekierska (11561278), Rafal M. Kaminski (12620842), Peter A. M. de Witte (11561275), James D. Mills (9418733), Michel Gillard (261248)   +8 more
core   +1 more source